CN101389213B - Pufa聚酮化合物合酶系统及其用途 - Google Patents

Pufa聚酮化合物合酶系统及其用途 Download PDF

Info

Publication number
CN101389213B
CN101389213B CN200480014646.XA CN200480014646A CN101389213B CN 101389213 B CN101389213 B CN 101389213B CN 200480014646 A CN200480014646 A CN 200480014646A CN 101389213 B CN101389213 B CN 101389213B
Authority
CN
China
Prior art keywords
seq
domain
pufa
schizochytrium
pufa pks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480014646.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101389213A (zh
Inventor
詹姆斯·G·梅茨
克雷格·A·韦弗
威廉·R·巴克利
詹姆斯·H·弗拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV, Martek Biosciences Corp filed Critical DSM IP Assets BV
Publication of CN101389213A publication Critical patent/CN101389213A/zh
Application granted granted Critical
Publication of CN101389213B publication Critical patent/CN101389213B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
CN200480014646.XA 2003-03-26 2004-03-26 Pufa聚酮化合物合酶系统及其用途 Expired - Fee Related CN101389213B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45797903P 2003-03-26 2003-03-26
US60/457,979 2003-03-26
PCT/US2004/009323 WO2004087879A2 (en) 2003-03-26 2004-03-26 Pufa polyketide synthase systems and uses thereof

Publications (2)

Publication Number Publication Date
CN101389213A CN101389213A (zh) 2009-03-18
CN101389213B true CN101389213B (zh) 2014-05-28

Family

ID=33131738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480014646.XA Expired - Fee Related CN101389213B (zh) 2003-03-26 2004-03-26 Pufa聚酮化合物合酶系统及其用途

Country Status (11)

Country Link
EP (1) EP1623008B1 (cg-RX-API-DMAC7.html)
JP (3) JP2007524377A (cg-RX-API-DMAC7.html)
KR (3) KR101234198B1 (cg-RX-API-DMAC7.html)
CN (1) CN101389213B (cg-RX-API-DMAC7.html)
AU (2) AU2004225485B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409046A (cg-RX-API-DMAC7.html)
CA (1) CA2520396C (cg-RX-API-DMAC7.html)
ES (1) ES2516641T3 (cg-RX-API-DMAC7.html)
IL (1) IL200625A0 (cg-RX-API-DMAC7.html)
MX (2) MX341785B (cg-RX-API-DMAC7.html)
WO (1) WO2004087879A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
EP1707055A3 (en) 2000-01-28 2009-01-14 Martek Biosciences Corporation Enhanced production of lipids containing polyenoic fatty acids by very high density cultures of eukaryotic microbes in fermentors
BRPI0613295A2 (pt) 2005-07-01 2010-12-28 Martek Biosciences Corp produto oleoso contendo ácido graxo poliinsaturado e usos e produção do mesmo
GB0603160D0 (en) * 2006-02-16 2006-03-29 Rothamsted Res Ltd Nucleic acid
WO2007106903A2 (en) 2006-03-15 2007-09-20 Martek Biosciences Corporation Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
EP2415360A3 (en) * 2006-08-29 2012-02-29 Martek Biosciences Corporation Use of DPA(n-6) oils in infant formula
WO2010101218A1 (ja) * 2009-03-04 2010-09-10 国立大学法人宮崎大学 微生物の脂肪酸合成経路の判別方法及びそれに用いるｐｃｒプライマーセット
CN102648207A (zh) 2009-03-16 2012-08-22 马太克生物科学公司 在网粘菌门微生物中产生蛋白质
ES2717102T3 (es) 2009-03-19 2019-06-19 Dsm Ip Assets Bv Moléculas de ácido nucleico de ácido graso poliinsaturado sintasas, y polipéptidos, composiciones y métodos de preparación y usos de los mismos
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR101570771B1 (ko) 2013-11-18 2015-11-23 대한민국 고도불포화지방산 생합성을 위한 재조합 벡터 및 이를 이용하여 제작된 형질전환 식물체
JP6682109B2 (ja) * 2015-01-09 2020-04-15 国立大学法人 宮崎大学 ヤブレツボカビ類を用いたリグニン分解活性を有するタンパク質の製造方法
EP3455351B1 (en) * 2016-05-12 2022-08-24 DSM IP Assets B.V. Method of increasing omega-3 polyunsaturated fatty acids production in microalgae
EP3835412A4 (en) * 2018-08-10 2022-05-11 Kyowa Hakko Bio Co., Ltd. POLYUNSATURATED FATTY ACID PRODUCING MICROORGANISM AND PROCESS FOR THE PRODUCTION OF POLYUNSATURATED FATTY ACID
WO2020032261A1 (ja) * 2018-08-10 2020-02-13 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140486A (en) * 1997-06-04 2000-10-31 Calgene Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) * 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
DK1911837T3 (da) * 2000-09-28 2011-08-29 Bioriginal Food & Science Corp FAD5-2 fedtsyredesaturasefamiliemedlem og anvendelser deraf
TWI426127B (zh) * 2001-04-16 2014-02-11 Ｄｓｍ智慧財產有限公司 多不飽和脂肪酸（ｐｕｆａ）聚乙醯合成酶系統及其用途（三）
CA2387401C (en) * 2001-05-21 2004-10-12 Ecopia Biosciences Inc. Compositions, methods and systems for the production of enediynes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140486A (en) * 1997-06-04 2000-10-31 Calgene Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants

Also Published As

Publication number Publication date
WO2004087879A3 (en) 2008-07-24
JP2016000048A (ja) 2016-01-07
BRPI0409046A (pt) 2006-04-18
JP2007524377A (ja) 2007-08-30
JP5890791B2 (ja) 2016-03-22
EP1623008A4 (en) 2009-05-27
JP6134361B2 (ja) 2017-05-24
ES2516641T3 (es) 2014-10-31
CN101389213A (zh) 2009-03-18
AU2008249169B2 (en) 2012-03-15
KR101234198B1 (ko) 2013-02-19
MX341785B (es) 2016-09-01
EP1623008B1 (en) 2014-07-30
JP2013143945A (ja) 2013-07-25
EP1623008A2 (en) 2006-02-08
CA2520396A1 (en) 2004-10-14
KR101234200B1 (ko) 2013-02-19
AU2008249169A1 (en) 2008-12-11
AU2004225485B2 (en) 2008-08-21
HK1088632A1 (en) 2006-11-10
AU2004225485A1 (en) 2004-10-14
WO2004087879A2 (en) 2004-10-14
KR20120097502A (ko) 2012-09-04
KR20120123726A (ko) 2012-11-09
MXPA05010214A (es) 2005-12-14
KR101234199B1 (ko) 2013-02-20
CA2520396C (en) 2016-08-09
IL200625A0 (en) 2011-07-31
KR20060006014A (ko) 2006-01-18

Similar Documents

Publication Publication Date Title
JP5806259B2 (ja) Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
JP6134361B2 (ja) Ｐｕｆａポリケチドシンターゼ系およびこれらの使用
US7259295B2 (en) PUFA polyketide synthase systems and uses thereof
US20100099154A1 (en) Pufa polyketide synthase systems and uses thereof
CN101437950A (zh) Pufa聚酮合酶系统及其用途
JP2005510203A6 (ja) Ｐｕｆａポリケチドシンターゼ系およびそれらの使用方法
AU2002303394A1 (en) PUFA polyketide synthase systems and uses thereof
HK1088632B (en) Pufa polyketide synthase systems and uses thereof
AU2012203480A1 (en) PUFA polyketide synthase systems and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: DSM IP ASSET LLP

Free format text: FORMER OWNER: MARTEK BIOSCIENCES BOULDER CORP.

Effective date: 20121115

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121115

Address after: Holland Heerlen

Applicant after: DSM IP asset company

Address before: American Maryland

Applicant before: Martek Biosciences Corp.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140528

Termination date: 20150326

EXPY Termination of patent right or utility model